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Abstract: Paclitaxel is a natural, highly lipophilic anti proliferative drug widely used in medicine. 18 
We have studied the release of tritium-labeled paclitaxel (3H-PTX) from matrices destined for the 19 
coating of vascular stents and produced by the electrospinning method from the solutions of 20 
polycaprolactone (PCL) with paclitaxel (PTX) in hexafluoisoropropanol (HFIP) and/or solutions of 21 
PCL with PTX and human serum albumin (HSA) in HFIP or HIFP-dimethyl sulphoxide (DMSO) 22 
blend. The release of PTX has been shown to depend on the solvent and the composition of 23 
electrospinning solution, as well as the composition of the surrounding medium, particularly the 24 
concentration of free PTX and PTX-binding biomolecules present in human serum. It was shown 25 
that 3D matrices can completely release PTX without weight loss. Two-phase PTX release from 26 
optimized 3D matrices was obtained: ~27% of PTX was released in the first day, another 8% were 27 
released over the next 26 days. Wherein ~2.8%, ~2.3%, and ~0.25% of PTX was released on day 3, 9, 28 
and 27, respectively. Considering PTX toxicity, the rate of its diffusion through the arterial wall, 29 
and the data obtained the minimum cytostatic dose of the drug in the arterial wall will be 30 
maintained for at least three months.  31 
Keywords: drug release; electrospinning; paclitaxel; polycaprolactone; 3D matrix. 32 
 33 
1. Introduction 34 
Nano- and microfiber-assisted drug delivery is actively studied worldwide. It is used 35 
in specific areas, such as tissue engineering [1] but also to solve general problems of drug 36 
delivery, such as enhancement of drug solubility [2] and tailoring of the kinetics of drug 37 
release [3]. Electrospinning (ES), i.e., the formation of polymer filaments from melts or 38 
solutions of polymers in a strong electric field, is a suitable method for the incorporation of 39 
drugs into the fibers and is frequently used for production of drug-enriched matrices. Nano- 40 
and microfibers produced by ES have a large surface area. Furthermore, their porosity, 41 
hydrophilicity/hydrophobicity, ability participate in to ionic and nonionic interactions, as 42 
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well as diameter and ultrastructure of the fibers can be tailored. In addition, it is possible to 43 
use polymers possessing different degradation rates [4]. The most convenient is ES of 44 
polymer solutions which can employ one or more polymers and drugs, emulsions and 45 
suspensions of drugs [5]. Fiber surface and porosity are usually modified by adding 46 
water-soluble biopolymers or low-molecular-weight components to the ES solution or using 47 
water- or thermo-induced phase separation [6]. The fibers of different structure can be 48 
produced by ES, including hollow, coaxial, and (multi)double-layered fibers combined with 49 
drugs introduced in different manners. These fibers can be produced simultaneously forming 50 
multi-fiber matrices or several different types of fibers, which can be arranged layer-by-layer 51 
in order to form multilayered matrices with different properties assigned to each layer [7]. 52 
The benefits of this approach are readily acknowledged, and electrospinning is widely used 53 
to fabricate drug-loaded materials, including bactericidal antibiotic dressings [8], growth 54 
factor-loaded 3D matrices capable of inducing cell proliferation and wound healing [9], and 55 
matrices with cytostatic drugs, used as anti-adhesive membranes [10]. 56 
Recently, electrospun matrices were suggested as coatings for bare-metal esophageal 57 
[11] and vascular stents [12]. The high incidence of restenosis requires the reassessment and 58 
improvement of current practices for the remodeling of stented arterial regions with 59 
bare-metal stents [13]. Restenosis is caused by the proliferation of smooth muscle cells of the 60 
arterial wall, endothelial cells or cells of atherosclerotic plaques induced by the mechanical 61 
action on the remodeled vessel, damage of the endothelial layer and other surrounding cell 62 
layers/tissues [14]. Induction of local inflammation in the stent region also promotes cell 63 
proliferation and neointima growth [15]. Drug-eluting stents covered with anti-proliferative 64 
or anti-inflammatory drugs such as sirolimus and paclitaxel (PTX) were proposed to reduce 65 
the proliferation of surrounding cells.  PTX is a natural, highly lipophilic, water-insoluble 66 
compound, which exhibits a cytotoxic antimitotic effect by activating the assembly of 67 
microtubules from tubulin dimers, stabilizing microtubules, and inhibiting the reorganization 68 
of the microtubular network in the interphase and during mitosis [13]. The lipophilicity of 69 
PTX allows its accumulation in the altered atheromatous vascular wall. The usual dose of 70 
PTX in paclitaxel-eluting stents is approximately 3 µg/mm2 [16]. Excessive doses were 71 
shown to induce the formation of aneurysms [17]. Therefore, blending of PTX with polymers 72 
was proposed to increase the effect of PTX i.e. short-term and long-term toxicity, while using 73 
lower concentrations of PTX. For example, the Eluvia stents (Boston Scientific Corporation, 74 
PTX with poly(vinylidene fluorideco-hexafluoropropylene) only contain 0.167 µg/mm2 PTX  75 
[18].  76 
In this work, we studied the release of PTX from the 3D matrices prepared from a 77 
solution of polycaprolactone (PCL) containing human serum albumin (HSA) intended for the 78 
coating of bare-metal stents. Such matrices have good mechanical characteristics and an 79 
extended region of elastic deformation, i.e. if used as a coating, they will not exert additional 80 
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loads on struts after stent expansion during installation. Moreover, the slow degradation rate 81 
of PCL may allow it to provide a lasting mechanical protection of the vessel lumen from 82 
stenosis. It is implemented in a similar way in the Inspire MD CGuard™ stents [19]. Release 83 
of PTX from matrices can be slowed by adding HSA, which binds PTX at Kd = 1.43 × 84 
104 M-1 [20] and acts as the main carrier of PTX in the human body. In addition, HSA has 85 
been shown to reduce platelet adhesion and increase thromboresistance and 86 
hemocompatibility of blood-exposed surfaces [21, 22]. With the task of creating a coating 87 
that can prevent cell proliferation for as long as possible, we developed and fabricated 3D 88 
matrices enabling prolonged PTX delivery. 3D matrices were produced by electrospinning 89 
and characterized by general methods including tensile strength, SEM, XPS, contact angle, 90 
ets, PTX release was studied using tritium-labeled PTX.  91 
2. Materials and Methods  92 
2.1. Production and quality control of tritium-labeled paclitaxel 93 
Tritium-labeled PTX (3H-PTX) was synthesized by thermoactivated tritium exchange 94 
as described earlier [23]. 3H-PTX was purified from by-products by reverse phase 95 
chromatography on a C18 column using a gradient of acetonitrile in water (25-100%). The 96 
radiochemical purity of the resulting compound was evaluated by autoradiography after thin 97 
layer chromatography (TLC) on Kieselgel 60 F254 plates (Merck, Germany, 25 Alufolien 20 98 
x 20 cm) in a chloroform-methanol-water mixture (19 : 1 : 0.1, Rf ~0.7). Radioactivity of the 99 
preparation was measured on a Tri-Carb 2800 TR β-counter (PerkinElmer, USA) in a 100 
“ULTIMA GOLD LTT” scintillator (Perkin Elmer, USA). An aliquot of the sample (0.1 mL) 101 
was thoroughly mixed with a scintillator (0.9 mL), and radioactivity was measured at the 102 
same time after preparation of the mixture. 103 
2.2. Preparation of 3D matrices by electrospinning. 104 
Electrospinning solutions were prepared using stock solutions of 9% PCL and 1% 105 
HSA (Sigma-Aldrich, USA) in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP, Sigma-Aldrich, 106 
USA). The HSA concentration in matrices is given as weight percentage (wt/wt) of total 107 
matrix weight. PTX (Sigma-Aldrich, USA) was dissolved in HFIP or DMSO 108 
(Sigma-Aldrich, USA) and added to the matrix (~0.46 μg/cm2, which corresponds to 0.36 109 
μg/disk). DMSO (3 or 6%, v/v) was added to the solution of polymers. 3H-PTX was diluted 110 
with unlabeled PTX to provide at least 26000 cpm/cm2 (or 20000 cpm/disk, 10 mm diameter 111 
disk, ~0.785 cm2). To produce the 3D matrices with 3H-PTX, a homemade electrospinning 112 
device with an airproof chamber and exhaust HEPA filter was used, equipped with a 113 
Spellman SL 150 (30 kV, Spellman, USA) power supply. Matrices of thickness of 150–180 114 
µm were prepared using a drum collector 2 cm in diameter and 5.2 cm in length (32.6 cm2) 115 
under the following conditions: feed rate, 1.2–1.4 mL/h; capillary-collector distance, 19–20 116 
cm; voltage, 23–25 kV; collector rotation speed, 300 rpm; temperature, 23–25°C; humidity, 117 
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25–35%. After fabrication, 3D matrices were removed from the collector, dried in vacuum 118 
under 10 Pa for 12 h and stored in sealed zip-lock polyethylene containers at 4°C. 119 
2.3. Characterization of matrices 120 
2.3.1. Mechanical testing of matrices 121 
Strain-stress diagrams were obtained using a universal Zwick/Roell Z100 (Germany) 122 
test bench as described in ISO 7198:1998 [24]. Electrospun matrices were carefully cut into 123 
10×50 mm rectangular shapes and placed between holders at a distance of 2–2.5 cm. Tensile 124 
strength testing was conducted at a rate of 10 mm×min−1 at room temperature (21–23°C). At 125 
least four specimens of each sample were tested. The residual load after two-fold elongation 126 
of matrices was measured in the same way, with the difference that after matrix elongation, 127 
the load was removed, the clamps of the tearing machine were returned to their original 128 
position (l0), and the load was re-measured after two-fold elongation of the matrix. 129 
2.3.2. Study of 3D matrix surface microstructure 130 
The microstructure of the matrix surface was studied by scanning electron 131 
microscopy (SEM) as described earlier [25]. The fiber diameter and pore size were evaluated 132 
from the SEM images according to ISO 7198:1998 [24]. To assess the stability of the fiber 133 
structure, the 3D matrices were incubated in phosphate buffered saline (PBS) 134 
(Sigma-Aldrich, USA) or human plasma at room temperature for 27 days. After the 135 
incubation, the matrices were rinsed with Н2О, air-dried, and examined by SEM. 136 
2.3.3. X-ray photoelectron spectroscopy  137 
The X-ray photoelectron spectroscopy (XPS) study was performed on a SPECS 138 
electron spectrometer equipped with a PHOIBOS-150 MCD-9 hemispherical analyzer and a 139 
non-monochromatic twin Mg-Al source (SPECS GmbH, Germany). To avoid thermal 140 
degradation of the sample, the X-ray gun was positioned at a distance of 30 mm from the 141 
sample holder and operated at MgKα irradiation power of 70W or less. The spectra were 142 
recorded with pass energy set to 50 eV (survey scans) and 10 eV (high-resolution ones). 143 
Before the measurements, the energy scale was calibrated using the Au4f7/2 (84.00 eV) and 144 
Cu2p3/2 (932.67 eV) peaks from gold and copper foils. The residual gas pressure during the 145 
spectra acquisition did not exceed 3 × 10−7 Pa. The samples were mounted on steel sample 146 
holders by using 3M® copper conductive double-sided adhesive tape. Quantitative data 147 
processing was performed using the XPSPEAK software version 4.1 and atomic sensitivity 148 
factors reported previously [26]. To study the influence of medium on 3D matrices, they 149 
were incubated in water or ethanol for 48 h, as described in 2.4, rinsed, air-dried, and stored 150 
as described in 2.2.  151 
2.3.4. Additional physicochemical characteristics of matrices  152 
The contact angle was measured on a Drop Shape Analyzer–DS A25 (Kruss GmbH, 153 
Germany) using water as a solvent (drop volume, 1 µL; shooting speed, 160 frames per 154 
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second). The porosity of the matrices was evaluated using matrix volume and PCL density 155 
according to the formula:  156 
Porosity (%) = [1 – Da/Dp] × 100, where Da is apparent density (matrix weight/matrix 157 
volume) and Dp is the polymer density.  158 
SEM data was also used for porosity calculations as described in ISO 7198:1998 159 
according to the formula:  160 
Porosity (%) = [Ap/(Am + Ap)] × 100, where Ap is pore area and Am is matrix area.  161 
Water absorption and weight loss of matrices were evaluated as described in ISO 7198:1998 162 
according to the formulas:  163 
Water absorption (%) = (Ww – Wo)/Wd × 100; 164 
Weight loss = (%) = (Ww – Wd/Wo) × 100, where Ww is weight after wetting, Wo is 165 
weight before wetting, and Wd is weight after wetting and drying under vacuum. The 166 
accuracy of measurements considering 3D matrices weight and accuracy of weighting was 167 
about 1.5%. Weight loss was evaluated after 27 days of incubation of 3D matrices in PBS as 168 
described in 2.3.2.  169 
The drying rate of the matrices was evaluated after soaking the matrices in water for 170 
24 h, followed by weight measurements on a microbalance with an accuracy of ±0.1 mg. 171 
2.4. Assessment of paclitaxel release 172 
To evaluate the PTX release, 10 mm disks were excised from matrices by die cutting, 173 
weighed with an accuracy of ±0.1 mg, and placed in wells of a 48-well plate. Disks were 174 
covered with 250 µL of PBS or EDTA-stabilized human plasma (HBP). The plate was sealed 175 
with a sealed adhesive film (Microseal® 'B' PCR Plate Sealing Film, adhesive, Bio-Rad, 176 
USA) to prevent drying, followed by incubation on a Titramax 1000 shaker (Heidolph, 177 
Germany) at 37°C and platform rotation speed of 200 rpm for different times up to 27 days. 178 
Two types of 3Н-PTX release kinetics were evaluated. For Series 1 the matrices were 179 
incubated with the solution for 20 min, 60 min, 3 h, 9 h, 27 h, 3 days, 9 days, and 27 days 180 
without medium replacement. For Series 2 at each time point the supernatant was removed, 181 
the matrix was rinsed, and incubated in a fresh replacement of the respective solution until 182 
the next time point, when the same procedure was repeated. After the incubation, the 183 
matrices were washed with distilled water and air-dried at room temperature. Radioactivity 184 
of the supernatants was measured in duplicate as described in section 2.1. The concentration 185 
of PTX in the solution was calculated from the specific radioactivity of the preparation, 186 
assuming that one disc contained ~0.36 μg of PTX. 187 
The influence of the matrix deformation on the 3Н-PTX release was studied as 188 
follows. A strip of a 3D matrix was fixed in clamps, the distance between the clamps was 189 
measured, and subsequently matrix was slowly stretched with a screw to double the 190 
measured distance. After removing the load, linear sizes of the strip were measured in order 191 
to recalculate amount of PTX per square cm, discs were excised from the deformed matrix, 192 
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and 3Н-PTX release was evaluated as described. All experiments were performed in 193 
duplicate. 194 
2.5. Statistical processing of data 195 
Microsoft Excel 2010 was used to handle and process the experimental data. 196 
Statistical analyses were performed using the Statistica 7.0 package (StatSoft Inc., USA). 197 
3. Results and Discussion 198 
3.1. Synthesis of radioactively labeled PTX 199 
 3H-PTX was synthesized by the thermoactivated tritium exchange as described earlier 200 
[23]. The RP-HPLC-purified 3Н-PTX preparation was obtained with a specific radioactivity 201 
of 1.5 mCi/mL (~0.3 Ci/mМ of PTX). According to the TLC data, the compound was 202 
homogenous and detected as one spot on the autoradiograph with Rf as non labeled PTX. 203 
Preliminary tests were performed to determine the optimal conditions for the measurement of 204 
the sample radioactivity in PBS and HBP. It was shown that the counting efficiency is 205 
inversely proportional to the volume of the sample; after the addition of the sample to 206 
scintillator at a ratio of 1:10 (v:v) no turbidity of the solution was detected, along with 207 
maximal efficacy of tritium detection independently of sample origin (H3 was detected with 208 
practically equal efficacy both in PBS and in human plasma). Therefore, the radioactivity of 209 
all samples was evaluated in the same way, i.e., 0.1 mL of the sample was diluted in the 210 
scintillator up to a total volume of 1 mL. The molar concentration of PTX was evaluated 211 
using the total specific radioactivity of the (3Н-PTX + PTX) preparation introduced into the 212 
matrix, which was ~47000 cpm/nM.  213 
3.2. Electrospinning and characterization of 3D matrices prepared from different mixtures of 214 
PCL with HSA and solvents 215 
HSA is known to be the main protein in the blood plasma, which binds PTX into two 216 
types of complexes with a common binding constant K=1.43 × 104 M-1 [20] and carries it in 217 
the blood. In electrospun 3D matrices prepared from PCL-HSA mixtures a significant 218 
amount of matrix-bound HSA is located on the fiber surface and remains exposed for a long 219 
time [25]. We consider that such matrices could be used as a coating for bare-metal vascular 220 
stents and delivery of PTX into the vascular wall. 221 
Conditions for preparation of matrices from PCL with HSA, PTX, and DMSO by 222 
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PCL/PTX  23.0 1.2 20 
PCL/PTX/10% HSA 23.5 1.3 20 
PCL/PTX/3% DMSO 23.0 1.3 20 
PCL/PTX/6% DMSO 24.5 1.3 20 
PCL/PTX/10% HSA/3%DMSO 24.5 1.4 20 
PCL/PTX/10% HSA/6% DMSO 25.0 1.4 20 
  230 
The strength of the PCL-based matrices was 3˗5.1 MPa depending on the 231 
composition of the electrospinning solution. The regions of elastic and plastic deformation 232 
for PCL-HSA matrices were 8±1.5% and 290 ±16%, respectively, which indicated their 233 
strength and elasticity compared to matrices prepared without the protein. Residual load after 234 
two-fold elongation was 1.4 ± 0.16 to 0.35 ± 0.07 MPa in the dry matrices and 1.0 ± 0.11 to 235 
0.26 ± 0.24 MPa in the wet matrices prepared from PCL/PTX/10% HSA and PCL/PTX/10% 236 
HSA/6% DMSO, respectively. The strength of the coronary artery wall is 1–2 MPa 237 
depending on the age of the donor and the presence of atherosclerotic lesions [27]. The 238 
thickness of the coronary artery wall is at least 2 mm [28], and the thickness of the stent 239 
coating is 0.1–0.15 mm. Therefore, the residual load in the coating of the stent after its 240 
installation does not exceed 5% of the load provided by the vascular wall. If the coatings for 241 
the metal stents are prepared from the solutions of PCL with HSA and DMSO, the load 242 
applied by the matrix on the stent struts will be no more than 1.5–2% of the load from the 243 
wall of the stented artery. Hence, from a mechanical point of view, the applicability of 244 
PCL-HSA 3D matrices for covering of vascular grafts was demonstrated. 245 
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 246 
Figure 1. Microstructure of 3D matrices (SEM, ×3000 magnification). The digit following 247 
the matrix composition indicates the incubation time of the matrices in PBS.  248 
 SEM analysis revealed that all prepared matrices were composed of microfibers with 249 
diameter determined by the composition of the electrospinning solution (Figure 1). Matrices 250 
from PCL and PCL with HSA consisted of fibers with average diameters of 0.32 and 0.56 251 
µm, respectively (Table 2). The addition of DMSO decreased the average fiber diameter 252 
(Figure 1, Table 2). The diameter of the fibers in 5% PCL/PTX/3% DMSO/HSA matrices 253 
was 0.37 ± 0.08 µm, which was the highest of all matrices with DMSO (from 0.13 to 0.19 254 
µm). The fibers of all matrices had a smooth surface. Using × 40000 magnification, with 255 
which structures as small as 20 nm can be resolved, no pores of diameter 10-20 nm could be 256 
detected on the fiber surface, although a slight roughness probably caused by the drying of 257 
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The data are presented as the mean ± error of the mean; 271 
*the first and the second numbers are porosity calculated from the apparent matrix density 272 
and the SEM data, respectively;  273 
**the contact angle was evaluated as a mean of at least five measurements in different parts 274 
of the matrix. 275 
 276 
The porosity of the fiber surface and the dependence of the pore size on 277 
electrospinning conditions, such as a solvent, polymer, and wetting, were studied previously 278 
[29, 30]. It was shown that pore formation is caused by the evaporation of the solvent and 279 
cooling of the surface of a newly formed fiber (thermally induced phase separation, TIPS) 280 
accompanying with condensation of water vapor (water induced phase separation, WIPS). 281 
The occurrence of pores only on the fiber surface as demonstrated previously by TEM and 282 
atomic force microscopy (AFM) is evidence in favor of WIPS rather than TIPS as the main 283 
determinant of fiber porosity [31]. Obviously, the interplay of solvent diffusion in polymers, 284 
polymer solubility in solvents, and phase transitions occurring for several polymers in the 285 
same solvent can play an important role in the formation of the structure and the surface of 286 
the fibers. Pore formation can lead to a significant increase in the surface area of electrospun 287 
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3D matrices up to ~100˗1000 m2/g [30], which undoubtedly will affect the rate and extent of 288 
drug release. 289 
Notably, it is often postulated that the nanopores in fibers are tortuous rather than 290 
straight and have a significant length [32]. Their size depends, among other factors, on the 291 
type of solvent as well as protein concentration and solubility. It should be noted that in the 292 
solvent systems, such as dimethylformamide/dichloromethane or dimethylformamide/ 293 
chloroform [33], proteins are poorly dissolved and are present in suspension. This fact can 294 
significantly influence the fiber structure, exposition of the proteins on fiber surface and the 295 
release of the protein from the fiber. In contrast, proteins including HSA are readily dissolved 296 
in HFIP with the preservation of their 3D structure [25] and thus the structure of fibers 297 
produced form HFIP should significantly differ from those previously mentioned.  298 
According to SEM, the incubation of matrices in PBS for 27 days had little effect on 299 
the structure of matrices made of pure PCL, PCL with HSA, and PCL with 6% DMSO. These 300 
results are consistent with the data obtained earlier, which showed that PCL matrices are 301 
stable for 12–24 months [34].  302 
Shrinkage of the material with thickening of fibers and increasing the number of 303 
interfiber contacts were observed in the matrices produced from PCL with 3% or 6% DMSO 304 
and with or without HSA. SEM demonstrates that the matrices with HSA tend to change 305 
morphology more than those without the protein (Figure 1). Apparently, the hydration of the 306 
fibers, which involves the hydration of the integrated HSA is the main factor. In other words, 307 
HSA molecules within the fiber promote diffusion of the water, hydration and swelling. It 308 
was demonstrated in our previous work that the size of HSA molecule in water exceeds its 309 
size in HFIP, by applying small-angle X-ray scattering [25]. Since incubation does not 310 
change the weight of the matrices, no significant degradation of the matrices can be observed. 311 
However, the change and reorganization of the fiber structure and HSA hydration can have a 312 
considerable effect on PTX release. 313 
The concentration distribution of added components on the matrix surface was 314 
evaluated by XPS (Figure 2). To evaluate the residual amounts of DMSO S2p XPS spectra of 315 
sulfur were acquired. The use of S2p signals for spectroscopic analysis of PCL-HSA matrices 316 
is rather complicated, since sulfur is a minor component of proteins. Fortunately, “organic” 317 
(C-S-H) and sulfoxide (C-S=O) states of sulfur have substantially different S2p positions on 318 
a binding energy scale. Indeed, the spectra of PCL-HSA samples have a distinct S2p peak at 319 
163.3 eV attributed to protein sulfur due to both its binding energy value and the signal 320 
intensity. At first glance, the smaller peak located at 166.3 eV could account for sulfur in 321 
DMSO moieties. However, it definitely includes N1s a “ghost peak” resulting from 322 
cross-contamination by AlKα radiation (ca. 1% in this case). The intensity of N1s ghost line 323 
(black curve in Figure 2B) well matched the intensity of the peak 163.3 eV in S2p spectrum. 324 
Thus, the samples carried no sulfur-containing moieties on their surface regardless of DMSO 325 
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content and treatment regimes, suggesting that PTX release could not be caused by the 326 
diffusion of DMSO from the matrices. 327 
 328 
Figure 2. S2p XPS spectra of the samples PCL + PTX + DMSO (A) and PCL + DMSO + 329 
HSA (B). 330 
Table 3 shows that the HSA content of the surface layer slightly decreased inversely 331 
proportionally to DMSO concentration, which may indicate that HSA is transported by the 332 
HFIP flow during fiber drying. As shown earlier [25], incubation of matrices in physiological 333 
solution leads to a reorganization of the surface layer and an increase in the HSA 334 
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Table 3. XPS data on HSA and PTX surface concentrations in electrospun 3D matrices 347 
obtained from different PCL/HSA or PCL/PTX blends  348 
No Sample of 3D matrix 
Concentration of HSA or PTX, % 
Initial matrix 
Matrix after 
incubation in PBS 
1 PCL/10% HSA 20* 24* 
2 5%PCL/10%HSA/3%DMSO  18.9 27.1 
3 5%PCL/10%HSA/6%DMSO 16.3 21.5 
4 5%PCL/PTX  21.1 23.4 
5 5%PCL/PTX/3%DMSO 15.1 23.9 
6 5%PCL/PTX/6%DMSO 3.7 13.7 
*According to (a study by) Chernonosova et al. 2017. [25] 349 
According to XPS results, the PTX concentration in the surface layer of the 350 
PCL-based 3D matrices also decreased inversely proportionally to DMSO concentration in 351 
ES solution (Table 2). Only 3.7% of PTX was detected in the surface layer of 352 
5%PCL/PTX/6%DMSO 3D matrices in contrast to 21% in the matrices from pure PCL. The 353 
increase in the PTX concentration on the surface of electrospun fibers was previously 354 
described for matrices prepared from PCL in dichloromethane [11]. The authors attributed 355 
this finding to the effect of solvent drying during ES.  356 
Similarly to HSA, PTX concentration in the surface layer increased after incubation 357 
of the matrices in the physiological solution, which was especially noticeable in the 5% PCL/ 358 
PTX/6% DMSO matrices made (10% PTX concentration increase). Apparently, wetting of 359 
the matrices leads to a structural reorganization of the fiber surface, and low PTX solubility 360 
in water [34] results in its accumulation on the matrix surface. Unfortunately, one is unable to 361 
use XPS to measure concentrations of PTX and HSA simultaneously. Considering the ability 362 
of HSA to bind PTX (in aqueous solution) and potential hydrophobic interactions between 363 
PTX and HSA one can consider that HSA exposed at fiber surface can additionally retain 364 
PTX, slowing down its release out of fibers.  365 
The detection depth of XPS is no more than 10 nm. In a 500 nm fiber, the 10 nm thick 366 
surface layer occupies approximately 8% of the total volume. Given that the percentage of 367 
PTX in the matrices is no more than 0.01%, even if all PTX were to concentrate in this layer, 368 
its concentration should not exceed 0.2%, as opposed to the 3.7-21% PTX concentration 369 
according to XPS data. For the weight balance to equalize, the PTX layer should have a depth 370 
of 1 nm (almost monolayer). Thus, a significant part of PTX is concentrated in the thin 371 
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surface layer of the fibers, which interfaces with the external medium and facilitates PTX 372 
release into the solution. 373 
The porosity of matrices calculated from the matrix volume and the density of the 374 
polymer composition varied in the range 77-80% and was not significantly different for 375 
matrices prepared from different solutions. The porosity evaluated by SEM was 54% to 76%, 376 
and the pore size varied from 5.7 to 0.97 µm. The matrices synthesized from DMSO 377 
solutions were less uniform, in terms of not only fiber diameter, but also the pore size (Table 378 
2, Figure 1). 379 
No weight loss of the matrices was detected after drying, even though matrices made 380 
of PCL with 10% HSA are known to release the protein into solution [25]. This loss could not 381 
be detected by gravimetric methods under the conditions of the experiment (the loss is 382 
0.2-0.3% of the matrix weight, provided that the matrix weight is no more than 5 mg, and the 383 
weight of released HSA is only 10-15 µg).  384 
Water absorption varied from 294% for the pure PCL matrices to 883% for 5% PCL/ 385 
PTX/6%DMSO/HSA matrices. According to a previous study based on the Washburn’s 386 
equation, the time required to fill nanopores is several microseconds [35], which means that 387 
the observed differences in water absorption cannot be caused by incomplete hydration of the 388 
matrices. The water absorption value is inversely proportional to the contact angle of 3D 389 
matrices and the fiber diameter. In addition, HSA-containing matrices retain more water than 390 
those without the protein, which is likely caused by the higher hydrophilicity of the 391 
HSA-containing matrices and the hydration of HSA within the fibers. 392 
The surface of PCL-based matrices without HSA was hydrophobic (Table 2), they 393 
were poorly wetted, and lost almost all water after the first drying period (Figure 3) [35]. The 394 
second drying period for these matrices was very short, which can indicate a rapid transport 395 
of water from the internal volume of the matrices and lack of interaction between water and 396 
matrix surface. 397 
PCL/HSA matrices had contact angle below 90°, indicating hydrophilicity. Provided 398 
that the density of PCL is 1.021 g/cm3, the matrix adsorbed no less than 589% of water 399 
(weight percentage) but quickly lost it during the first drying period. The hydrophilic fiber 400 
surface retains the water to a greater extent, therefore, explaining the longer second drying 401 
period typical for these matrices.  402 
PCL/HSA/DMSO matrices were more hydrophilic compared to those without HSA 403 
and absorbed significantly more water (Table 3). Apparently, the mass transfer of water in 404 
these matrices is determined by not only by the flow from the hydrostatic drop pressure 405 
occurring due to filling of pores of different radii (as described by Laplace’s law) but also the 406 
interaction of water with the fiber surface. Indeed, mass transfer may include 407 
surface-diffusion flows, film formation, and the occurrence of disjoining pressure, which can 408 
lead to fluid transfer in surface films when their thickness deviates from the equilibrium 409 
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value (surfaces with ultrastructural disturbances are filled preferentially) [35]. Matrices with 410 
HSA and DMSO exhibited pronounced first and second drying periods, with the latter lasting 411 
longer and resulting in a higher water loss as compared to matrices without DMSO (Figure 412 
3). Judging by this, the microstructure of such matrices has similar characteristics, although 413 
matrices with 6% DMSO had a lower contact angle and were more thoroughly filled with 414 
water. These matrices were also more heterogeneous in fiber diameter (Figure 1), consisted 415 
of thinner fibers and had a more branched surface. 416 
 417 
 418 
Figure 3. Drying rate of 3D matrices. The data presented as means, error of the mean does 419 
not exceed 7%. 420 
3.3. PTX release from matrices 421 
It is known that hydrophilic matrices have a lower capacity to adsorb proteins [36] 422 
and induce inflammation and, therefore, have advantages over hydrophobic matrices as 423 
materials for implants [37]. Introduction of HSA decreases the contact angle, thus making 424 
matrices more hydrophilic (Table 2) and increasing their hemo- and biocompatibility [21, 425 
22]. The introduction of 3% or 6% of DMSO in PCL matrices did not lead to a significant 426 
change in the contact angle but affected matrix structure, fiber diameter, and water 427 
absorption, thus effectively increasing the area of medium-matrix interface. The two-phase 428 
nature of drying and high interface surface characteristic of the matrices with HSA and 429 
DMSO compared to other 3D matrices allow one to hope that PTX can be released 430 
effectively from such matrices and that its release kinetics would also follow a two-phase 431 
profile. 432 
As mentioned in “Materials and Methods”, PTX release from the matrices was 433 
studied without (1) or with the replacement of the media (2), i.e., the solution was replaced by 434 
the new portion after each time point. The selected conditions emulate PTX release into the 435 
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bloodstream (medium replacement) and in the vascular wall (no or slow replacement of 436 
medium).  437 
It should be noted that mathematical modelling of the mechanisms of drug delivery 438 
controlled by diffusion, osmosis, swelling/dissolution processes, etc is well-developed [38]. 439 
The release of low-molecular-weight compounds (Rhodamine 610) from electrospun 440 
matrices made of PCL [32] or bovine serum albumin (BSA) from PCL/BSA matrices [39] 441 
was studied earlier. The delivery of rhodamine was shown to be limited by its diffusion from 442 
fibers. The authors developed a theoretical model of the release and evaluated its parameters, 443 
such as nanoporosity and desorption enthalpy. They showed that the release is saturable - 444 
only a portion of rhodamine can be released, the precise amount depending on the fiber pore 445 
structure. Diffusion of this part of the compound from the fibers took between two and our 446 
days and the fibers no longer release rhodamine. Materials exhibiting this type of the release 447 
are poor candidates for stent coatings. Moreover, the authors did not attempt to enhance the 448 
bio- and hemocompatibity of the matrices and only studied the release of rhodamine and 449 
protein molecules from synthetic polymers.  450 
The kinetic curves of PTX release are presented in Figure 4. The release in PBS from 451 
5%PCL/PTX and 5% PCL/PTX/10%HSA matrices appears to be similar to that described 452 
earlier [32] with a saturation time of three days (Figure 4 A). However, some differences 453 
were observed, which were probably caused by the low solubility of PTX (less than 0.3 mg/L 454 
or 3.5 µМ in water). When incubated with medium replacement, PTX was released from the 455 
fibers past the third day and for as long as up to 27 days, and the total amount released was 456 
double the PTX release in PBS without medium replacement (Figure 4 B).  457 
 458 
Figure 4. Kinetics of PTX release from matrices. (A) Incubation of 3D matrices with PBS 459 
without medium replacement; (B) Incubation of 3D matrices with PBS with medium 460 
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replacement after each time point; (C) Incubation of 3D matrices with human plasma without 461 
medium replacement; (D) Incubation of 3D matrices with human plasma with medium 462 
replacement after each time point. 463 
In a fiber PTX can be found both in the volume and on the surface: PTXtotal = 464 
PTXvolume + PTXsurface. One can assume that without medium replacement, an equilibrium 465 
between PTX on the surface and PTX in the solution is achieved during the first three days 466 
(in PBS). Because of the low PTX solubility in water, the rate at which the equilibrium is 467 
established is limited by its desorption from the matrix surface. In the case of medium 468 
replacement, dissolved PTX is periodically removed, leading to additional desorption of 469 
PTX from the fibers into the solution, thus increasing the amount of dissolved PTX over 470 
time. Moreover, in HSA-containing matrices, the sorption/desorption on the fiber surface is 471 
accompanied by the binding of PTX to HSA (Kа = 1.43×104 M-1 [20]), which can retain PTX 472 
both within and on the surface of the fibers. 473 
During the incubation of matrices with plasma without replacement, the nature of the 474 
release did not change but saturation was achieved in five–seven days (Figure 4 C) and more 475 
PTX was released (55–60% vs 45%). When incubated with plasma replacement, PTX was 476 
completely released from matrices in three days (Figure 4 D). Apparently, HSA in plasma 477 
binds dissolved PTX, which prevents the resorption of PTX on the matrix surface. The 478 
concentration of HSA-bound PTX can be evaluated by taking into account the following 479 
factors: HSA concentration in plasma is ~1 mM; PTX concentration is ~0.82 µM; when 50% 480 
of this compound is released from the matrix (MWPTX is 854, the matrix contains 0.36 µg, the 481 
solution volume is 0.25 mL); association constant is Kа = 1.43×104 M-1. Using material 482 
balance equations, the concentration of the PTX-HSA complex is calculated as 0.77 µM. 483 
Thus, under these conditions, 94% of released PTX is associated with HSA. It is likely that 484 
other biomolecules in plasma can also be involved, e.g., lipids can interact with fat-soluble 485 
PTX on the surface or even within the matrix.  486 
Since incubation with plasma replacement increased the PTX release to 100%, PTX 487 
diffusion rate within the fibers/matrix did not limit the rate of PTX release. It should be noted 488 
that, according to SEM data, the fiber structure of these 3D matrices also did not change 489 
during long term incubation and PTX release into the solution (Figure 1) that is, the 490 
degradation or reorganization of the matrix structure is not associated with long-term PTX 491 
release.  492 
The results indicate that 5%PCL/PTX and 5%PCL/PTX/10%HSA matrices are not 493 
suitable for the prolonged delivery of the drug because they do not facilitate the long time 494 
two-phase kinetics of PTX release and the drug is rapidly released when matrix is in contact 495 
with human plasma. To obtain 3D matrices, which are capable of prolonged PTX release, it is 496 
necessary to either change the fiber structure or alter the PTX distribution in the fibers. To 497 
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retain PTX in the fiber during the solvent drying step and/or obtain the porous fibers, DMSO 498 
was added to the electrospining solution because its nontoxic, has a high boiling point 499 
(189°С), and dissolves PTX. In previous reports, the factor of matrix nanoporosity has been 500 
theoretically explored [30]. The authors of this report used a similar solvent system for 501 
electrospinning - a mixture of dimethylformamide (Tbp = 153°С) with dichloromethane (Tbp 502 
= 40°С). It was shown that the addition of 3% DMSO in the electrospinning solution 503 
significantly decreased the total PTX release into PBS (up to 25–35%) under conditions 504 
without medium replacement (Figure 4 A). For matrices with 6% DMSO the PTX release 505 
was slightly decreased, while almost no decrease of the total PTX release was observed in 506 
medium replacement conditions (Figure 4 B). These data are consistent with XPS 507 
demonstrating a decrease of PTX on the surface of 3D matrices electrospun from the 508 
solutions with DMSO (Table 3). As in previous cases, the rate of PTX diffusion from the 509 
fiber/matrix volume to its surface does not limit the rate of PTX transfer into the solution 510 
since no change in the total release of PTX under the conditions with medium replacement 511 
was detected.  512 
In regards to PTX release into the plasma, the addition of 6% of DMSO slightly 513 
decreased the release under the conditions with plasma replacement (Figure 4 D) but had no 514 
effect on PTX release without replacement (Figure 4 C). It should be noted that the matrices 515 
prepared from DMSO-containing solutions consist of thinner fibers as compared with the 516 
other matrices. Moreover, 3D matrices produced from ES solutions with 6% of DMSO are 517 
characterized by more hydrophobic surfaces, lower water adsorption, and lower amount of 518 
PTX on the surface according to the XPS data as compared with the matrices prepared from 519 
the solutions containing 3% DMSO. 520 
Generally speaking the matrices prepared from solutions containing DMSO and HSA 521 
are characterized by a slow release of PTX (Figures 4 C and 4 D). Matrices made from the 522 
5%PCL/PTX/3%DMSO/10%HSA released ~30% and 60% of PTX in 28 days under the 523 
conditions, both with and without medium replacement, respectively. The daily release of 524 
PTX decreased from ~25% (day 1) to 0.05% (day 28) and from ~45% (day 1) to 0.26% (day 525 
28) under the conditions, both with and without medium replacement, respectively. These 526 
results indicate the effect of DMSO, which changes the matrix structure and the distributions 527 
of both PTX and HSA in the fibers (Tables 2 and 3). 528 
Thus, the composition of ES solution and outside medium significantly affects the 529 
rate of the PTX release. The removal of dissolved PTX due to the medium replacement 530 
and/or binding to HSA, both prevent its resorption and lead to the fast diffusion of PTX from 531 
the fibers and its complete release from the matrix. Thus, desorption of PTX from fibers is 532 
the rate-limiting stage of PTX release. The results for matrices produced from ES solution 533 
with DMSO show that increased hydrophobicity of 3D matrices reduces desorption of PTX 534 
from the fiber surface. In addition, HSA in PCL fibers has a more pronounced PTX retention 535 
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effect. 3D matrices produced from solutions of PCL, HSA and DMSO in HFIP exhibited a 536 
pronounced two-phase kinetics profile of PTX release into PBS or human plasma. The first 537 
phase is the fast release due to desorption of PTX from the surface, the second stage is the 538 
slow PTX release caused by its interaction with HSA located within the hydrophobic fibers.  539 
Earlier, it was shown that rhodamine was only partly released into aqueous solutions 540 
from electrospun fibers prepared from PCL solutions in 541 
dimethylformamide/dichloromethane mixture, and a portion of rhodamine localized in the 542 
solid polymer phase, is never released [32]. Our results demonstrate that PTX can completely 543 
diffuse from the matrices prepared from PCL or PCL/HSA in HFIP with or without DMSO 544 
when the matrices are incubated with the human plasma (Figure 4 D). According to the XPS 545 
data (Table 2), a significant amount of PTX is exposed on the matrix surface, and the 546 
incubation of matrices with aqueous solutions led to a release of PTX (Figure 4) and 547 
reorganization of the surface layer, resulting in a further increase in the PTX concentration on 548 
the matrix surface (Table 2). Apparently, the structure of the fibers prepared from HFIP 549 
solutions and chemical properties of PTX allow this compound to be redistributed in the 550 
fibers. In any case, the matrices capable of complete PTX release are optimal for facilitating 551 
its delivery.  552 
The data on structure of 3D matrices (Tables 2 and 3) are strongly correlate with 553 
release of PTF from fibers. Actually, fibers able to accumulate PTX in their bulk and 554 
swelling during incubation demonstrated slower PTX release kinetics. It is interesting to note 555 
that water loss by matrices correlates with kinetics of PTX release (Figures 3 and 4).  556 
Stretching of the matrices to the point of two-fold elongation did not affect the PTX 557 
release. Both the nature of the release and the amount of released PTX per one unit of the 558 
matrix weight remained unchanged. However, the elongation of the matrices led to plastic 559 
deformation because of the small area of elastic deformation (7–10%), and the linear size of 560 
the matrices increased to 125–185% after loading. The amount of PTX released from 561 
elongated matrices was proportionally lower compared to untreated matrices. It is necessary 562 
to take this into account when optimizing the cytostatic dose of the drug for stent coating.  563 
 The nature of PTX release from 3D matrices containing HSA and DMSO and 564 
electrospun from HFIP solutions enables their use as coatings for vascular stents intended to 565 
prevent restenosis and proliferation of cell in the vascular wall. The perivascular delivery of 566 
PTX at concentrations from 20 to 230 µM under the conditions of internal pressure ensures 567 
its efficient accumulation in the artery walls, with predominant localization in the adventitia 568 
area [40]. According to some authors, the diffusion coefficient for PTX in arterial wall varies 569 
from 1×10-8 cm2/s to 4.87×10-6 cm2/s [41]. It is interesting to note that the diffusion 570 
coefficient for HSA (the main transporter of PTX) in the aortal wall (evaluated without 571 
regard to potential binding in the adventitia) is 1.06×10-8 cm2/s [42] and the protein is 572 
retained in the region of elastin fibers localized in the smooth muscle layer of the adventitia 573 
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[43]. In addition, it has been shown that elastin itself binds PTX and can promote its retention 574 
in the artery wall [44]. The accumulation of PTX in this layer can be mediated by PTX 575 
binding to both HSA and elastin. The toxic PTX concentration against smooth muscle 576 
myocytes is ~10 nM [45]. Providing that the matrix contains 0.46 µg/cm2 of PTX and 1% of 577 
it is released daily, the PTX concentration in the wall will be equal to or higher than its toxic 578 
concentration. One should take into account the initial accumulation of PTX in the wall, its 579 
low solubility, and the binding with the components of the extracellular matrix. Thus, the 580 
coating of bare-metal stents with scaffolds electrospun from the solutions of PCL with HSA 581 
and DMSO and containing 0.46 µg/cm2 of PTX can be toxic against vascular wall myocytes 582 
for at least three months. Herewith, the PTX dose, which is released during the first days after 583 
the stent implantation, will make it possible to eliminate the proliferation of activated cells, 584 
and high PTX concentration will compensate for its diffusion through the partially destroyed 585 
artery wall immediately after implantation. Furthermore, the data on the complete PTX 586 
release from the matrices produced from the HFIP solutions of PCL allows one to hope for an 587 
even more prolonged release of PTX from the fibers. It should also be noted that the change 588 
in the structure of the matrices during incubation, their shrinkage, and fiber aggregation, 589 
resulting in the reduction of the phase interface, could prolong the PTX release from the 590 
fibers and thus assist the cytotoxic effect of drugs introduced in such matrices. 591 
4. Conclusions 592 
The physicochemical properties of electrospun matrices prepared from the solutions 593 
of PCL with PTX in HFIP and their blends with HSA and DMSO were studied. It was shown 594 
that 3D matrices produced from a HFIP solution of PCL with PTX, HSA and DMSO are the 595 
most suitable to be used as coatings for bare-metal stents because they are not expected to 596 
exert any significant additional stress on the stent beams, exhibit long time two-phase 597 
kinetics of PTX release, and thus are expected to be able to maintain a cytotoxic PTX 598 
concentration in the vascular wall for at least three months. It was shown that PTX can be 599 
completely released from these matrices without fiber degradation. The use of plasma as the 600 
external medium accelerated PTX release, while two-fold elongation of 3D matrices did not 601 
interfere with the kinetics of the release. Thus, PCL-based 3D matrices containing HSA, PTX 602 
and DMSO can be used for the production of coated vascular stents with prolong delivery of 603 
PTX. 604 
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